Oncology Ventures (Texas Oncology Ventures) Research
Overview
Oncology Ventures (branded as Texas Oncology Ventures in partnership contexts) is a specialized, Austin-based venture capital firm founded in 2022 by cancer survivor Ben Freeberg. The fund invests exclusively in healthcare data companies tackling the biggest problems in cancer care — from early detection and precision diagnostics to care navigation, survivorship, and the non-drug infrastructure that makes treatment work. The firm has a sharply defined anti-thesis: it does not invest in drugs, therapeutics, or medical devices.
Note: The domain texasoncologyventures.com referenced in the task appears to be a Texas Oncology partnership initiative domain, while the primary firm website is oncology.ventures.
Investment Thesis
Oncology Ventures targets the fragmented and inefficient U.S. oncology market, which represents $210–$225 billion in annual spend growing at 12% annually. Approximately 1,700 Americans die from cancer daily, with over 1,000 of those deaths considered avoidable. The fund's thesis is that data-driven technology — applied across the entire cancer journey from early detection through survivorship — can meaningfully reduce mortality while also reducing costs for employers, health systems, and payers.
The firm focuses on infrastructure, data, IT, and services in oncology rather than clinical treatments. This "picks and shovels" approach gives Oncology Ventures a distinct identity in a sector where most cancer-focused VCs back therapeutics or devices.
Stage Focus and Check Size
Oncology Ventures invests primarily at the Seed and Series A stages:
- Seed investments: Average round size ~$6M; typical check $250K–$1.5M (Fund I era), likely expanded for Fund II
- Series A investments: Average round size ~$11.2M
- Series B: Selective follow-on participation
The firm looks for commercially-validated startups — companies that have moved beyond concept-stage and can demonstrate early traction in the oncology system.
Funds
Fund I: $32 million (closed ~2023, oversubscribed from $30M target). Anchored by City of Hope, Moffitt Cancer Center, Cardinal Health, and Atlantic Health.
Fund II: $62 million (closed April 2026, oversubscribed from $50M target, nearly double Fund I). New LP anchor: Texas Oncology (the largest physician-led oncology network in America, 550+ physicians, 300+ locations, 250,000+ unique patients annually). The LP network collectively treats approximately one in three cancer patients in the U.S.
Total AUM: ~$94M across both funds.
Lead Tendency and Decision Process
Ben Freeberg operates as the primary decision-maker, described as solo GP with a small team. The firm has led or co-led a number of rounds (e.g., Reimagine Care, mPATH). Decision process is concentrated with the founding GP.
Portfolio Overview
As of May 2026, Oncology Ventures has made 14+ investments across both funds. Key portfolio companies:
- mPATH Health (mpathhealth.com): Lung cancer screening navigation; 57% improvement in screening completion, proven across 15 published studies
- Tono Health (tonohealth.com): Virtual-first supportive oncodermatology managing skin toxicity side effects; 15,000+ patients supported
- RISA Labs (risalabs.ai): AI operating system for oncology workflow automation and prior authorizations; demonstrated $2M in annual savings at a single health system
- OncoveryCare (oncoverycare.com): Virtual survivorship clinic for cancer survivors, mental and physical health support
- Concr (concr.co): Precision oncology platform using ML and digital twins for biomarker discovery; improved median survival from 1.5 to 9.7 years in clinical data
- SpotDoc (spotdoc.com): Full-body 3D imaging and mapping for melanoma/skin cancer detection
- IgniteData (ignitedata.com): Patient data infrastructure for clinical trials; saved 70 hours per patient for research coordinators while cutting lab queries by 90%
- CancerNavigator (cancernavigator.com): Cancer patient routing and care navigation platform; 1M+ Americans with access through health plans
- Lumonus (lumonus.com): AI-native clinical infrastructure for oncology workflows; raised A$28M Series B
- Gabbi (gabbi.com): AI-powered breast cancer risk assessment and early detection for women
- Health Universe (healthuniverse.com): Enterprise AI platform automating complex healthcare workflows; raised $6M seed (2026)
- Reimagine Care (reimaginecare.com): Virtual-first cancer care and recovery; raised $25M Series A
- Modicus Prime (modicusprime.com): AI compliance platform for pharma; raised $8M total (Oncology Ventures participant, May 2026)
Team
Ben Freeberg, Founder & Managing Partner: Former VP at Optum Ventures (UnitedHealth's VC arm) and first employee at Alpha Partners. Helped build Thyme Care (value-based cancer care). Six-year cancer survivor. BSc Economics, Duke University.
Nandita Kotwani, Venture Associate: Led digital product development at Memorial Sloan Kettering; advised community oncology practices at Flatiron Health; Administrative Fellow at City of Hope. MHA from Columbia University.
Jay Freeberg, CFO: CPA, CFP. Partner emeritus at NYC accounting firm (24 years); extensive financial planning and investment management background since 1986.
Advisory Board includes: Dr. Karen Knudsen (CEO, Parker Institute for Cancer Immunotherapy), Nancy Brown (GP, Oak HC/FT), Brad Hively (former CEO, The Oncology Institute), Dr. Lee Newcomer (former CMO, UnitedHealth Group), Emily Melton (Co-founder, Threshold Ventures), Carolyn Starrett (CEO, Flatiron Health), Jennifer Malin MD (former CMO, Optum Health).
Geographic Focus
Primarily United States, with selectivity toward major cancer care markets. HQ in Austin, Texas. Portfolio includes at least one international company (Lumonus, Australian). LP network spans leading U.S. cancer centers.
Founder Preferences
The firm backs founders building data and technology solutions within the oncology care continuum. Strong preference for commercially-validated startups with demonstrated clinical or operational impact. Founders with deep oncology domain knowledge or healthcare data expertise are well-positioned.
Notable LP Network (Strategic Advantage)
Oncology Ventures' LP base is an unusually powerful strategic asset. LPs include Texas Oncology, Moffitt Cancer Center, City of Hope, Atlantic Health, Cardinal Health/Navista, Fred Hutch, and The James Cancer Hospital at Ohio State. These institutions collectively treat ~1 in 3 U.S. cancer patients and provide portfolio companies with unparalleled access to clinical partnerships, data, and validation pathways.